Innovative Australian biotechnology company Marinova Pty Ltd is celebrating its 20th anniversary throughout 2023.

The 2023 milestone marks two decades of dedication to the development and production of high purity seaweed extracts for the betterment of human health. Marinova is the global leader in the research, development and manufacture of fucoidan compounds – highly bioactive polysaccharides derived from select species of brown seaweed.

Speaking of the corporate milestone, company CEO Mr Paul Garrott said, “The unrivalled quality and efficacy of Marinova’s bioactive fucoidan extracts is based on two decades of rigorous scientific investigation and the development of the unique Maritech® extraction process. It is by virtue of this proprietary process that Marinova remains the world’s only producer of high purity, certified organic fucoidan with global regulatory acceptance.”

Marinova’s Australian made fucoidan extracts are exported to over 35 countries for inclusion in nutritional, cosmetic and animal health applications. The company’s high purity fucoidan fractions are also utilised in medical devices and form the basis of cutting-edge pharmaceutical research.

Coinciding with the 20th anniversary, Marinova is undertaking a $4.6M expansion of its state-of-the-art fucoidan extraction facility in Tasmania, Australia. The significant capital expansion will allow the company to triple its fucoidan production capacity in line with rising global demand.

To mark its third decade, Marinova has accelerated scientific research into the bioactive properties of its unique fucoidan extracts. “Marinova has always invested significantly in scientific research and has recently extended its research commitment by a further $5M over the coming years,” finished Mr Garrott. “Natural, certified organic, efficacious and sustainably sourced ingredients that are supported by an extensive scientific dossier of scientific evidence are rare – and in high global demand. Marinova’s commitment to science remains unwavering.”